RCC adjuvant pembroluzimab benefit estimation for 5y OS - Evidencio
RCC adjuvant pembroluzimab benefit estimation for 5y OS

This tool estimates the 5-year survival benefit of 1-year adjuvant anti-PD1 treatment after surgical R0 resection for clear-cell renal cell carcinoma (ccRCC). The calculation uses the average death-rate per year of any cause in The Netherlands (CBS), the cancer-specific survival based on the Leibovich score (2018 version) and the hazard ratio (HR) for adjuvant anti-PD1 therapy based on the KN-564 study.

Sex is only relevant for the death-of-any-cause estimation, not for adjustment of the KN-564 HR. The HR can be adjusted for WHO ECOG performance, based on the KN-564 findings: without ECOG input the model uses 0.62, for ECOG-1 0.82 and for ECOG-0 0.55. The 10y survival prediction is for consultation without adjuvant therapy only, as current HR can not be extrapolated that far in the future.

Forfattere til forskning: Ingen
Version: 2.0
  • Offentlig
  • Onkologi
  • {{ modelType }}
  • Detaljer
  • Validering af algoritme
  • Gem input
  • Indlæsning
Skærm
Enheder

{{section.title}}

Beregn resultatet

Indstil flere parametre for at udføre beregningen

Out of a 100 treated patients, Patients will survive anyhow for 5 years or more

{{ resultSubheader }}
{{ chart.title }}
Resultat-interval {{ additionalResult.min }} til {{ additionalResult.max }}

Betinget information

Please don't forget to counsel your patient for participation in the PRO-RCC national cohort!

{{ file.classification }}
PRO
Bemærk
Noter er kun synlige i resultatdownloadet og gemmes ikke af Evidencio.

Denne algoritme er beregnet til uddannelses-, trænings- og informationsformål. Den må ikke bruges til at støtte medicinsk beslutningstagning eller til at levere medicinske eller diagnostiske ydelser. Læs vores fulde disclaimer.

Underliggende algoritmer En del af
Kommentarer
Kommentar
Skriv venligst en kommentar
Kommentarer er synlige for alle

Algoritme-feedback

Ingen feedback endnu 1 kommentar {{ model.comments.length }} Kommentarer
På {{ comment.created_at }} {{ comment.user.username }} en ikke længere registreret forfatter skrev:
{{ comment.content }}
logo

Log ind for at aktivere Evidencios printfunktioner

For at kunne bruge Evidencios printfunktioner, skal du være logget ind.
Hvis du ikke har en Evidencio Community-konto, kan du oprette en gratis personlig konto på:

https://www.evidencio.com/registration

Trykte resultater - Eksempler {{ new Date().toLocaleString() }}


Fordele ved en Evidencio Community-konto


With an Evidencio Community account you can:

  • Create and publish your own prediction algorithms.
  • Share your prediction algorithms with your colleagues, research group, organization or the world.
  • Review and provide feedback on algorithms that have been shared with you.
  • Validate your algorithms and validate algorithms from other users.
  • Find algorithms based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction algorithms and their data.
  • Use patient specific protocols and guidelines based on sequential algorithms and decision trees.
  • Stay up-to-date with new algorithms in your field as they are published.
  • Create your own lists of favorite algorithms and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.


Ansvarsfraskrivelse: Beregninger alene bør aldrig diktere patientpleje og er ingen erstatning for professionel dømmekraft.
Evidencio v3.35 © 2015 - 2025 Evidencio. All Rights Reserved